Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

101. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma

Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

102. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. (Full text)

Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. The dose-response relationship of inhaled fluticasone propionate (FP) for adrenal suppression in adults with asthma is not clear. The current authors carried out a systematic review and meta-analysis of placebo-controlled randomised dose-response studies of >or=4 weeks' duration, which assessed the adrenal effects of FP by cosyntropin stimulation tests in adult asthma. The main outcome (...) secondary outcome measures showed an inverse linear relationship with the FP dose up to 2,000 microg.day(-1). In conclusion, for routine prescribing within the established therapeutic dose-response range (50-500 microg.day(-1)), fluticasone propionate has minimal effects on adrenal function. This conclusion is limited by the paucity of long-term studies of daily doses of fluticasone propionate >1,000 mug and by the considerable individual variability in the response.

2006 The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology PubMed abstract

103. Dose-response studies of fluticasone propionate and budesonide: classification based on asthma severity. (Abstract)

Dose-response studies of fluticasone propionate and budesonide: classification based on asthma severity. There are discrepancies in the results of dose-response studies of inhaled steroids. Although some studies show a dose-response relationship, others show no change in outcome with increasing the dose of inhaled steroids. These discrepancies are partly caused by the heterogeneity of dose-response studies. One area of heterogeneity is the subjects' level of asthma severity at baseline (...) . The objective of this study was to classify dose-response studies of two widely used inhaled steroids for asthma, fluticasone propionate (FP), and budesonide (BUD), according to the subjects' level of asthma severity at baseline. A PubMed search, limited to the English language and human subjects, was conducted from January of 1983 to January of 2004, using "dose response and budesonide" (331 articles) and "dose-response and fluticasone" (211 articles). Bibliographies of selected articles were searched

2006 Allergy and Asthma Proceedings

104. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. (Abstract)

Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. The relative efficacy of fluticasone (FP) and beclomethasone (BDP) propelled with CFCs has been well established. The potency of HFA-BDP is thought to have been improved with new propellant and some studies suggest that it may equipotent at half the dose of CFC propelled-BDP. There is a need to revisit this question in the light of a potentially more potent new non-CFC propellant.To determine

2006 Cochrane database of systematic reviews (Online)

105. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. (Abstract)

Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Wheezing and asthma often begins in early childhood, but it is difficult to predict whether or not a wheezy infant will develop asthma. Some researchers suggest that treatment with inhaled corticosteroids at the first signs of wheezing in childhood could prevent the development of asthma later in life. However, other investigators have reported (...) that although such treatment could help control symptoms, the benefits can disappear within months of stopping treatment. We tested our hypothesis that to prevent loss of lung function and worsening asthma later in childhood, anti-inflammatory treatment needs to be started early in life.We did a randomised, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young children who were followed prospectively and randomised after either one prolonged (>1 month) or two

2006 Lancet Controlled trial quality: predicted high

106. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

107. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. (Full text)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. Ciclesonide is a new inhaled corticosteroids licensed for the prophylactic treatment of persistent asthma in adults. Currently beclomethasone dipropionate, budesonide and fluticasone propionate are the most commonly prescribed inhaled corticosteroids for the treatment of asthma but there has been no systematic review comparing the effectiveness (...) and safety ciclesonide to these agents. We therefore aimed to systematically review published randomised controlled trials of the effectiveness and safety of ciclesonide compared to alternative inhaled corticosteroids in people with asthma.We performed literature searches on MEDLINE, EMBASE, PUBMED, the COCHRANE LIBRARY and various Internet evidence sources for randomised controlled trials or systematic reviews comparing ciclesonide to beclomethasone or budesonide or fluticasone in adult humans

2006 BMC family practice PubMed abstract

108. Inhaled fluticasone versus placebo for chronic asthma in adults and children. (Abstract)

Inhaled fluticasone versus placebo for chronic asthma in adults and children. Inhaled fluticasone propionate (FP) is a relatively new inhaled corticosteroid for the treatment of asthma.1. To assess efficacy and safety outcomes in studies that compared FP to placebo for treatment of chronic asthma.2. To explore the presence of a dose-response effect.We searched the Cochrane Airways Group Trial Register (January 2004), reference lists of articles, contacted trialists and searched abstracts

2005 Cochrane

109. [Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment]. (Abstract)

[Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment]. 15326966 2005 02 15 2015 11 19 0012-7183 120 13 2004 Duodecim; laaketieteellinen aikakauskirja Duodecim [Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment]. 1591-3 Sovijärvi Anssi R A AR HUSLAB, kliinisen (...) fysiologian ja isotooppilääketieteen laboratoriot, HUS. Haahtela Tari T Ekroos Heikki J HJ Lindqvist Ari A Saarinen Antti A Poussa Tuija T Laitinen Lauri A LA fin Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Hengitettävä kortikosteroidi vähentää keuhkoputkien supistumisherkkyyttä astmassa luultua nopeammin. Finland Duodecim 0373207 0012-7183 0 Androstadienes CUT2W21N7U Fluticasone IM Administration, Inhalation Adolescent Adult Androstadienes administration & dosage Asthma

2005 Duodecim; laaketieteellinen aikakauskirja Controlled trial quality: uncertain

110. Fluticasone given once versus twice a day: meta-analysis. (Abstract)

Fluticasone given once versus twice a day: meta-analysis. The aim of this study was to examine the efficacy of fluticasone administered once daily compared to twice daily in asthma.A meta-analysis was performed of randomized double-blind trials of at least 4 weeks duration that compared fluticasone administered once versus twice a day and presented data on at least one clinical outcome measure.Six studies of 1517 children and adults with asthma met the inclusion criteria. Studies were (...) predominantly in subjects with moderate asthma, treated with doses of fluticasone ranging from 200 to 500 microg per day. Twice-daily dosing was associated with significantly greater efficacy compared with once-daily dosing, for all outcome measures except night wakenings. The mean (95% CI) differences between twice and once-daily administration for FEV(1) and peak expiratory flow were 0.11 L (0.07-0.16) and 12.9 L/min (8.6-17.1), respectively. Twice-daily fluticasone was associated with significantly fewer

2005 Respirology (Carlton, Vic.)

111. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. (Abstract)

Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma. Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays.To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.We searched the Cochrane Airways Group trial (...) register (January 2004) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997 to 2003).Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma.Two reviewers independently assessed articles for inclusion and methodological quality. One reviewer extracted data. Quantitative analyses were undertaken using

2005 Cochrane database of systematic reviews (Online)

112. Inhaled fluticasone at different doses for chronic asthma in adults and children. (Abstract)

Inhaled fluticasone at different doses for chronic asthma in adults and children. Inhaled fluticasone propionate (FP) is a high-potency inhaled corticosteroid used in the treatment of asthma.1. To assess the efficacy and safety outcomes of inhaled fluticasone at different nominal daily doses in the treatment of chronic asthma. 2. To test for the presence of a dose-response effect.We searched the Cochrane Airways Group Trials Register (January 2005) and reference lists of articles. We contacted (...) trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997 to 2004).Randomised trials in children and adults comparing fluticasone at different nominal daily doses in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data. These were checked and verified by a second reviewer. Quantitative analyses where undertaken using RevMan (Analyses 1.0.2

2005 Cochrane database of systematic reviews (Online)

113. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. (Abstract)

Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. The relative efficacy of fluticasone (FP) and beclomethasone (BDP) propelled with CFCs has been well established. The potency of HFA-BDP is thought to have been improved with new propellant and some studies suggest that it may equipotent at half the dose of CFC propelled-BDP. There is a need to revisit this question in the light of a potentially more potent new non-CFC propellant.To determine

2005 Cochrane database of systematic reviews (Online)

114. Fluticasone versus placebo for chronic asthma in adults and children. (Abstract)

Fluticasone versus placebo for chronic asthma in adults and children. Inhaled fluticasone propionate (FP) is a relatively new inhaled corticosteroid for the treatment of asthma.1. To assess efficacy and safety outcomes in studies that compared FP to placebo for treatment of chronic asthma.2. To explore the presence of a dose-response effect.We searched the Cochrane Airways Group Specialised Register (January 2005), reference lists of articles, contacted trialists and searched abstracts of major

2005 Cochrane database of systematic reviews (Online)

115. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) , Stanford R, Crim C, Yancey S W, Edwards L, Rickard K A, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of three alternative first-line maintenance treatments for asthma control: fluticasone propionate (100 microg

2004 NHS Economic Evaluation Database.

116. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) , Rickard K, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two combination treatments for patients with persistent asthma were examined. One was fluticasone propionate (FP) 100 microg and salmeterol (SAL) 50 microg

2004 NHS Economic Evaluation Database.

117. Clinical dose-response relationship of fluticasone propionate in adults with asthma. (Full text)

Clinical dose-response relationship of fluticasone propionate in adults with asthma. A study was undertaken to examine the dose-response relation of inhaled fluticasone in adolescents and adults with asthma.A meta-analysis was carried out of randomised clinical trials that presented data on at least one outcome measure of asthma and that used at least two doses of fluticasone given twice daily. The main outcome measures were forced expiratory volume in 1 second (FEV1), morning peak expiratory (...) for FEV1 and amPEF resulting from an increase in dose from 200 to > or =500 microg/day was 0.07 l (95% CI -0.01 to 0.14) and 5.9 l/min (95% CI -3.0 to 15.3), respectively. The odds ratio for withdrawals with 200 microg/day compared with > or =500 microg/day was 1.27 (95% CI 0.78 to 2.07).In adolescents and adults with asthma, most of the therapeutic benefit of fluticasone is achieved with a total daily dose of 200 microg/day with minimal further clinical benefit achieved with higher doses

2004 Thorax PubMed abstract

118. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. (Abstract)

Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays.To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.We searched the Cochrane Airways Group trial register (January 2003 (...) ) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997 to 2003).Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data. Quantitative analyses were undertaken using RevMan analyses 1.0.1.48

2004 Cochrane database of systematic reviews (Online)

119. Systematic review of the dose-response relation of inhaled fluticasone propionate. (Full text)

Systematic review of the dose-response relation of inhaled fluticasone propionate. To examine the dose-response relation of inhaled fluticasone for both efficacy and adrenal function in children with asthma.Systematic review of double blind randomised dose-response studies of fluticasone in children of at least 4 weeks duration.FEV1, morning peak expiratory flow, night awakenings, beta agonist use, major exacerbations, 12 or 24 hour urinary cortisol, peak plasma cortisol post-stimulation.Seven (...) urinary cortisol between placebo and fluticasone at doses of 100 and 200 microg per day. The non-placebo controlled study of 528 children reported significant suppression of overnight urinary cortisol levels with fluticasone at 400 compared with 200 microg per day.There is insufficient data to determine the dose-response of fluticasone in children at doses >400 microg per day. The dose-response curve for fluticasone appears to plateau between 100 and 200 microg per day for efficacy

2004 Archives of disease in childhood PubMed abstract

120. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. (Abstract)

The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Intranasal corticosteroids have been shown to decrease ocular symptoms associated with allergic rhinitis as well as nasal symptoms. The primary objective of this retrospective analysis was to evaluate the efficacy of fluticasone propionate (FP) aqueous nasal spray in the treatment of ocular symptoms in patients with seasonal allergic rhinitis (SAR). We pooled efficacy

2003 Allergy and Asthma Proceedings